ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Scale Biosciences and Basepair to Democratize Single Cell Sequencing Data Analysis

Scale Biosciences, a pioneer in single-cell sequencing technology, today announced a new collaboration with Basepair to provide point and click bioinformatic analysis of single-cell data produced with its patented and disruptive combinatorial indexing technology. As a result of this collaboration, scientists will be able to access Scale Biosciences’ optimized bioinformatics pipeline through a user-friendly, web-based, graphical user interface (GUI), enabling their organizations to quickly adopt new single-cell protocols, regardless of their in-house bioinformatics capabilities.

The initial deployment of the ScaleBio Seq Suite on the Basepair platform will allow researchers to upload both fastq and BCL files and use an intuitive GUI to quickly analyze their data and generate reports for individual samples and entire libraries. These include reports to help researchers assess their data quality and produce a cell-gene matrix compatible with open-source standard single-cell analysis workflows like Seurat and Scanpy. The collaboration will also make it easier for customers to adopt Scale Biosciences technology without investing in additional IT and bioinformatics infrastructure by providing a secure way to upload and store data in the cloud.

“Challenges related to analysis and interpretation of sequencing data are still one of the most common bottlenecks that researchers face when adopting new next-generation sequencing applications, especially those that create large amounts of data,” said Giovanna Prout, CEO of Scale Biosciences. “We want the scientific community to have access to bioinformatics options that fit their budget and help answer their research questions. Through our relationship with Basepair, we are making it easier for organizations with limited resources to quickly and cost effectively go from sample to interpretable data.”

"At its core, Basepair enables tools manufacturers like Scale Biosciences to better support research scientists with any computational background,” said Amit Sinha, PhD, Founder of Basepair. “With our groundbreaking federated approach to analysis, we look forward to helping Scale Biosciences’ customers better understand their data and accelerate their research without it ever needing to leave their direct control.”

Learn more about Scale Biosciences single-cell technology at https://scale.bio/.

About Scale Biosciences

ScaleBio is a single-cell sequencing solutions company founded by a multidisciplinary team of scientists and technologists with combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics, and a common mission for unlocking the potential of single-cell analysis at scale by eliminating barriers to discovery. ScaleBio is financed by leading life sciences tools investors ARCH Venture Partners, BNG and Tao Capital. ScaleBio has R&D facilities in San Diego and Menlo Park, CA.

About Basepair

Basepair Inc is a bioinformatics company focused on unlocking the full potential of next generation sequencing (NGS) technology. By empowering more scientists to understand the meaning and value of genomic data while keeping it secure in-place, we help accelerate the scientific and diagnostic breakthroughs that bring lifesaving medicines and treatments to the patients that need them. To learn more, visit www.basepairtech.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.